{"id":999,"date":"2017-07-27T14:51:52","date_gmt":"2017-07-27T05:51:52","guid":{"rendered":"http:\/\/iij.webpacklab.com\/wp\/?page_id=712"},"modified":"2017-09-04T13:45:55","modified_gmt":"2017-09-04T04:45:55","slug":"antibodymedical","status":"publish","type":"page","link":"https:\/\/www.tokumen.co.jp\/en\/study\/antibodymedical\/","title":{"rendered":"Antibody pharmaceutical"},"content":{"rendered":"\n<div id=\"keybox\">\n<div class=\"title title_cat3\">\n<h2>Antibody pharmaceutical<\/h2>\n<\/div>\n<div id=\"breadcrumb\">\n<nav class=\"single\">\n<ol>\n<li><a href=\"\/en\/\">HOME<\/a><\/li>\n<li><a href=\"\/en\/study\/\">Research and Development<\/a><\/li>\n<li>Antibody pharmaceutical<\/li>\n<\/ol>\n<\/nav><\/div>\n<\/p><\/div>\n<p>\t<main role=\"main\"><\/p>\n<article id=\"pages_area\">\n<section class=\"pages inviewUp\">\n<div class=\"cntbox\">\n<h2>TKM-011 (Humanized anti-CD20 antibody\uff09<\/h2>\n<div class=\"textonly\">\n<ul>\n<li>A potent cytotoxic effects against Rituximab-resistant lymphoma cells.<\/li>\n<li>Unique epitope not shared with Rituximab.<\/li>\n<\/ul><\/div>\n<div class=\"imgonly\">\n<div class=\"imgbox\"><img decoding=\"async\" src=\"https:\/\/www.tokumen.co.jp\/wp\/wp-content\/themes\/iij_custom\/images\/pages\/img_d3_07_01en.png\" alt=\"\"><\/div>\n<\/p><\/div>\n<h2>FIH Test of TKN-011 for Lymphoma Patients<\/h2>\n<div class=\"textonly\">\n<ul>\n<li>The phase I study was done in two hospitals in Japan.<\/li>\n<li>No dose-limiting toxicities, related serious adverse events were observed.<\/li>\n<li>Effective for almost all patients with relapsed or refractory non-Hodgkin\u2019s lymphoma.<\/li>\n<\/ul><\/div>\n<div class=\"imgonly\">\n<div class=\"imgbox\"><img decoding=\"async\" src=\"https:\/\/www.tokumen.co.jp\/wp\/wp-content\/themes\/iij_custom\/images\/pages\/img_d3_07_02en.png\" alt=\"\"><\/div>\n<\/p><\/div>\n<p>\t\t\t\t\t<!--\n\n<h3>1\uff0c\u8a66\u9a13\u30c7\u30b6\u30a4\u30f3<\/h3>\n\n\n\t\t\t\t\t\n\t\t\t\t\t\n\n<div class=\"imgonly\">\n\t\t\t\t\t\t\n\n<div class=\"imgbox\"><img decoding=\"async\" src=\"https:\/\/www.tokumen.co.jp\/wp\/wp-content\/themes\/iij_custom\/images\/pages\/img_d3_07_02.png\" alt=\"\"><\/div>\n\n\n\t\t\t\t\t<\/div>\n\n\n\t\t\t\t\t\n\t\t\t\t\t\n\n<h3>2\uff0c\u5b89\u5168\u6027 <\/h3>\n\n\n\t\t\t\t\t\n\t\t\t\t\t\n\n<div class=\"textonly\">\n\t\t\t\t\t\t\n\n<ul>\n\t\t\t\t\t\t\t\n\n<li>Infusion related reaction\u304c\u307b\u307c\u5168\u4f8b\u3067\u8a8d\u3081\u3089\u308c\u305f\u304c\u3001\u5236\u5fa1\u53ef\u80fd\u3067\u3042\u3063\u305f\u3002<\/li>\n\n\n\t\t\t\t\t\t\t\n\n<li>DLT\u306e\u767a\u73fe\u306a\u3057\u3002<\/li>\n\n\n\t\t\t\t\t\t\t\n\n<li>\u6297BM-ca\u6297\u4f53\u306e\u767a\u73fe\u306a\u3057\u3002<\/li>\n\n\n\t\t\t\t\t\t\t\n\n<li>\u305d\u306e\u4ed6\u6709\u5bb3\u4e8b\u8c61\u306fRituximab\u3068\u540c\u5185\u5bb9\u30fb\u540c\u7a0b\u5ea6\u3002<\/li>\n\n\n\t\t\t\t\t\t<\/ul>\n\n\n\t\t\t\t\t<\/div>\n\n\n\t\t\t\t\t\n\t\t\t\t\t\n\n<h3>3\uff0c\u6297\u816b\u760d\u6d3b\u6027; \u307b\u307c\u5168\u75c7\u4f8b\u3067\u816b\u760d\u4f53\u7a4d\u306e\u6e1b\u5c11\u304c\u898b\u3089\u308c\u305f\u3002<\/h3>\n\n\n\t\t\t\t\t\n\t\t\t\t\t\n\n<div class=\"imgonly\">\n\t\t\t\t\t\t\n\n<div class=\"imgbox\"><img decoding=\"async\" src=\"https:\/\/www.tokumen.co.jp\/wp\/wp-content\/themes\/iij_custom\/images\/pages\/img_d3_07_03.png\" alt=\"\"><\/div>\n\n\n\t\t\t\t\t<\/div>\n\n--><\/p>\n<h2>Rationale of B-cell Depletion Therapy for PBC*<\/h2>\n<div class=\"textonly\">\n<ul>\n<li>The autoantibodies and autoreactive CTL are involved in PBC pathogenesis.<\/li>\n<li>B-cell depletion therapy can provide better outcome in patients with PBC like RA and MS.\n<\/li>\n<\/ul><\/div>\n<div class=\"imgonly\">\n<div class=\"imgbox\"><img decoding=\"async\" src=\"https:\/\/www.tokumen.co.jp\/wp\/wp-content\/themes\/iij_custom\/images\/pages\/img_d3_07_04en.png\" alt=\"\"><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<\/article>\n<p>\t<\/main><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibody pharmaceutical HOME Research and Development Antibody pharmaceutical TKM-011 (Humanized anti-CD20 antibody\uff09 A potent cytotoxic effects against Rituximab-resistant lymphoma cells. Unique epitope not shared with Rituximab. FIH Test of TKN-011 for Lymphoma Patients The phase I study was done in two hospitals in Japan. No dose-limiting toxicities, related serious adverse events were observed. Effective for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":997,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"53","footnotes":""},"class_list":["post-999","page","type-page","status-publish","hentry","en-US"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/pages\/999"}],"collection":[{"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/comments?post=999"}],"version-history":[{"count":1,"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/pages\/999\/revisions"}],"predecessor-version":[{"id":1039,"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/pages\/999\/revisions\/1039"}],"up":[{"embeddable":true,"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/pages\/997"}],"wp:attachment":[{"href":"https:\/\/www.tokumen.co.jp\/wp-json\/wp\/v2\/media?parent=999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}